Final overall survival (OS) results of a noncomparative phase II study of bevacizumab (B) plus first-line chemotherapy or second-line erlotinib (E) in nonsquamous …
B Besse, S Le Moulec, H Senellart, J Mazieres… - 2013 - ascopubs.org
8059 Background: The non-comparative BRAIN study (NCT00800202) is the first trial to
evaluate efficacy/acceptable safety of B in pts with ns-NSCLC and untreated BM. We report …
evaluate efficacy/acceptable safety of B in pts with ns-NSCLC and untreated BM. We report …
[HTML][HTML] Phase II study of bevacizumab in combination with 1st-line chemotherapy or 2nd-line erlotinib in non-squamous NSCLC (NS-NSCLC) patients with …
B Besse, S Le Moulec, H Senellart, J Mazieres… - Annals of …, 2012 - Elsevier
Background Brain metastases (BM) occur in up to 56% of pts with advanced cancer and are
no longer a contraindication to bevacizumab treatment based on safety data. The non …
no longer a contraindication to bevacizumab treatment based on safety data. The non …
Bevacizumab in patients with nonsquamous non–small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study
B Besse, S Le Moulec, J Mazières, H Senellart… - Clinical Cancer …, 2015 - AACR
Purpose: The phase II prospective, noncomparative BRAIN study (NCT00800202)
investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated …
investigated efficacy and safety of bevacizumab in chemotherapy-naïve or pretreated …
Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer
WL Akerley, CJ Langer, Y Oh, DK Strickland… - Journal of Clinical …, 2008 - ascopubs.org
8043 Background: Bevacizumab (Bv)+ carboplatin/paclitaxel received FDA approval in
10/06 for improving survival in first-line treatment of advanced NSCLC patients (pts) without …
10/06 for improving survival in first-line treatment of advanced NSCLC patients (pts) without …
Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial …
GA Otterson, PG O'Connor, M Lin, RS Herbst… - Journal of Clinical …, 2009 - ascopubs.org
e19025 Background: Bevacizumab (B)+ carboplatin/paclitaxel received FDA approval in
10/06 for improving survival in first-line treatment of advanced NSCLC patients (pts). In the …
10/06 for improving survival in first-line treatment of advanced NSCLC patients (pts). In the …
A phase II trial of bevacizumab in patients with recurrent solid tumor brain metastases who have failed whole brain radiation therapy (WBRT).
2070 Background: Brain metastases (BM) are the most common intracranial malignancy
with overall a poor prognosis estimated at approximately 4 months from time of initial …
with overall a poor prognosis estimated at approximately 4 months from time of initial …
Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases
AS Berghoff, MO Breckwoldt… - Neuro-oncology …, 2020 - academic.oup.com
Background Salvage treatment for recurrent brain metastases (BM) of solid cancers is
challenging due to the high symptomatic burden and the limited local treatment options …
challenging due to the high symptomatic burden and the limited local treatment options …
Safety of bevacizumab-containing chemotherapy in non-small-cell lung cancer patients with brain metastases
N Kuse, K Yoshimori, M Ueyama, I Hirukawa… - Annals of Cancer …, 2012 - jstage.jst.go.jp
Introduction: Patients with brain metastases have commonly been denied bevacizumab
treatment because of the suspected risk of central nervous system (CNS) hemorrhage …
treatment because of the suspected risk of central nervous system (CNS) hemorrhage …
Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer
KC De Braganca, YY Janjigian, CG Azzoli… - Journal of neuro …, 2010 - Springer
Bevacizumab is effective for the treatment of non-small cell lung cancer (NSCLC). Ongoing
trials are exploring the safety of bevacizumab in patients with inactive, previously treated …
trials are exploring the safety of bevacizumab in patients with inactive, previously treated …
MA 03.05 Bevacizumab combined with chemotherapy for patients with advanced NSCLC and brain metastasis. A French Cohort Study
J Bennouna, L Falchero, R Schott, F Bonnetain… - Journal of Thoracic …, 2017 - jto.org
Background Although brain metastases (BM) are a very common and clinically challenging
for NSCLC progression, there are few prospective studies addressing the safety and efficacy …
for NSCLC progression, there are few prospective studies addressing the safety and efficacy …